Vaccines as treatment strategies for relapsed prostate cancer: Approaches for induction of immunity

Hematology/Oncology Clinics of North America

Volumn 15, Issue 3, 2001, Pages 477-496

  Slovin, S F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DENDRITIC CELL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT INDICATION;

EID: 0034889738     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70227-6     Document Type: Article

References (58)

1. Cellular mucins: Targets for immunotherapy
2. Expression of heterologous sequences in adenoviral vectors
3. Total synthesis of a human breast tumor associated antigen
4. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer
5. Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells
6. Gene therapy for human prostate cancer
7. b blood group determinants and of H-type I and H-type II oligosaccharides
8. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
9. Gene immunotherapy in murine acute myeloid leukemia granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B 7 family and other cytokine vaccines
10. A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA) in advanced prostate cancer
11. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
12. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity
13. Immunologic approaches to the treatment of prostate cancer
14. Inducing immunity to prostate specific antigen (PSA) in prostate cancer patients
15. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes
16. Gene transfer into mammalian cells by particle bombardment. Anal Biochem
17. GD3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines
18. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
19. Gene therapy for prostate
20. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: Implications for cytotoxic T lymphocyte responses and tumor burdens
21. The central role of CD4(+) T cells in the antitumor immune response
22. Generation of allo-reactive cytotoxic T lymphocytes by particle bombardment-mediated gene transfer
23. CTLA 4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary cancer
24. High efficiency gene transfer into primary human tumor explants without cell selection
25. Generation of PSA-specific effector T-cells after vaccination with PSA-based vaccines in patients with prostate cancer
26. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast
27. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
28. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
29. The current status of gene therapy for prostate cancer
30. Immunization of mice with a fully synthetic globo-H antigen results in antibodies against human cancer cells: A combined chemical-immunological approach to the fashioning of an anticancer vaccine
31. A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle
32. Analysis of human tumor associated Thomsen-Friedenreich antigen
33. Demonstration of a rational strategy for human prostate cancer gene therapy
34. A phase I trial of G3139, a BCL2 antisense drug, by continuous infusion (CI) as a single agent and with weekly Taxol (T)
35. Intermediate markers in assessing response to vaccine therapies
36. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
37. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice
38. Targeted therapy for prostate cancer: The Memorial Sloan-Kettering Cancer Center Approach
39. Targeted therapy in prostate cancer (PC): Vaccination with a glycoprotein, MUC-1-KLH-QS21 peptide conjugate
40. Carbohydrate-based vaccines for the treatment of relapsed cancer
41. Carbohydrate vaccine in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
42. MUC-2-KLH conjugate vaccine: Immunogenicity in patients with relapsed prostate cancer
43. Ganglioside vaccines in relapsed prostate cancer (PC): Experience with GM2-KLH conjugate plus the immunologic adjuvant, QS21-A trial comparing QS21 doses
44. Tn-cluster (c)-KLH/PAM vaccine conjugates in biochemically relapsed prostate cancer (PC): Phase I trial results
45. Construction of fowlpox virus vectors with intergenic insertions: Expression of the beta-galactosidase gene and the measles virus fusion gene
46. The dendritic cell system and its role in immunogenicity
47. Adenoviral vector mediated high efficiency gene transfer in prostate cancer cell lines
48. Gene therapy: Principles and potential
49. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity
50. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
51. Gene therapy approaches in urologic oncology
52. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
53. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4
54. Cytokine mediated immunogene therapy in rat prostate cancer model
55. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides
56. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen
57. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
58. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines